Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5000 participants
OBSERVATIONAL
2020-03-01
2020-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The population of congenital heart disease (CHD) might also be at risk, however, no data is available in this group of patients.
CHD is the leading cause of birth defects, and as a result of recent medical advances, currently the number of adults with CHD exceeds the number of children, with an increasing prevalence of complex CHD. Approximately 200,000 children and 250,000 adults are living with a CHD in France today.
The French Society of Cardiology, coordinator of this study, issued recommendations on March 14, 2020 for the French CHD population on the basis of expert opinions based essentially on the data published in the general population. Nevertheless, there is a need to provide scientific data on the impact of Covid-19 in the pediatric and adult CHD population.
This study aims to assess the morbidity, the mortality and the risk factors associated with Covid-19 in patients with CHD in France
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Covid-19, Acute Myocardial Infarctions and Strokes in France
NCT04542083
Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry
NCT04359927
Impact of Assessment and Management of Comorbidities in Internal Medicine on Cardiovascular Risk
NCT06204549
Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study
NCT04357314
Elucidating the Symptomatic, Explanatory and Prognostic Characteristics of GERIAtric Patients Hospitalized for COVID-19
NCT04560608
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Covid-19 infection over the study period
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pr. Jean-Benoît THAMBO, Bordeaux (président)
UNKNOWN
Dr. Céline GRUNENWALD GRONIER, Strasbourg
UNKNOWN
Dr. Sébastien HASCOET, Le Plessis-Robinson
UNKNOWN
Dr. Adeline BASQUIN, Rennes
UNKNOWN
Dr. Nicolas COMBES, Toulouse
UNKNOWN
Dr. Xavier IRIART, Bordeaux
UNKNOWN
Dr. Daniela LAUX, Paris
UNKNOWN
Dr. Magalie LADOUCEUR, Paris
UNKNOWN
Pr. BERTRAND LEOBON, Toulouse
UNKNOWN
Pr. Caroline OVAERT, Marseille
UNKNOWN
Dr. Karine WARIN-FRESSE, Nantes
UNKNOWN
Alexis BLANC, Montpellier
UNKNOWN
Pr. Roland HENAINE, Lyon
UNKNOWN
Hamouda ABASSI, Montpellier
UNKNOWN
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pascal AMEDRO, MD-PhD
Role: STUDY_DIRECTOR
UH MONTPELLIER
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uh Montpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation. 2007 Jan 16;115(2):163-72. doi: 10.1161/CIRCULATIONAHA.106.627224. Epub 2007 Jan 8.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. No abstract available.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL20_0155
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.